# Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI)

> **NCT00251732** · PHASE4 · COMPLETED · sponsor: **University of Arizona** · enrollment: 150 (actual)

## Conditions studied

- Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** Standard dose (once daily) PPI plus low-dose antidepressant
- **DRUG:** Double dose PPI plus evening placebo
- **DRUG:** Rabeprazole , placebo, placebo

## Key facts

- **NCT ID:** NCT00251732
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2010-08-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00251732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00251732, "Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00251732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*